Navigation Links
WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008

Earnings Conference Call to be held on March 13, 2008 at 9:00 am (Eastern)

/ 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong)

SHANGHAI, China, Feb. 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or "the Company"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the fourth quarter and full year ended December 31, 2007 after the US market close on Wednesday, March 12, 2008.

(Logo: )

The earnings release will be available on the investor relations page of its website at .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 9:00 am (Eastern) / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Thursday, March 13, 2008 to discuss its 2007 fourth quarter and full year financial results and recent business activity. The conference call may be accessed by calling:

United States

Toll Free: +1-888-596-2633

Toll: +1-913-312-1234

China, Northern Region

Toll Free: +10-800-714-0970

China, Southern Region

Toll Free: +10-800-140-0945

Hong Kong

Toll Free: +800-965-503

United Kingdom

Toll Free: +0808-101-1402

A telephone replay will be available shortly after the call until April 12, 2008 at (US) +1-888-203-1112/ (HK) +800-901-108 / (China, Southern Region) +10-800-140-1178 / (China, Northern Region) +1-719-457-0820 / (UK) +0808-101- 1153. Passcode: 2224172.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at .

About WuXi PharmaTech (Cayman) Inc.

WuXi PharmaTech, headquartered in Shanghai, China, is the leading global pharmaceutical, biotechnology and medical device R&D outsourcing company. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory, research manufacturing, biologics testing and manufacturing services throughout the drug and medical device research and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device research and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. For more information, please visit: .

For more information, please contact:

Investor Contact:

Dr. Hai Mi, Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd

Tel: +86-21-5046-3726


Investor Relations (US):

Mahmoud Siddig, Director

Taylor Rafferty

Tel: +1-212-889-4350


Investor Relations (HK):

Ruby Yim, Managing Director

Taylor Rafferty

Tel: +852-3196-3712


Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350


SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Completes Acquisition of AppTec
2. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
3. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
4. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
5. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
8. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
9. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
10. WuXi PharmaTech Announces Second Quarter 2007 Results
11. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
Post Your Comments:
(Date:11/26/2015)... England , November 26, 2015 ... an innovative medical device company specializing in imaging technologies, announced ... the European Commission as part of the Horizon 2020 European ... to carry out a large-scale clinical trial in breast cancer. ...      (Logo: , --> ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
Breaking Biology News(10 mins):